RP1联合纳武利尤单抗治疗抗PD-1失败晚期黑色素瘤
RP1(vusolimogene oderparepvec)是一种基于单纯疱疹病毒1型的溶瘤免疫疗法,联合纳武利尤单抗用于抗PD-1治疗失败的晚期黑色素瘤患者。在140例患者中,确认的客观缓解率(ORR)为32.9%,中位缓解持续时间33.7个月,1年和2年总生存率分别为75.3%和63.3%,安全性良好。
要点
- 抗PD-1失败晚期黑色素瘤中,RP1联合纳武利尤单抗确认ORR达32.9%。
- 中位缓解持续时间33.7个月,1年和2年OS率分别为75.3%和63.3%。
- 安全性良好,大多数不良事件为1/2级,无5级事件。
核心结论
- RP1联合纳武利尤单抗在抗PD-1失败黑色素瘤中提供深度且持久的全身缓解,包括预后不良因素患者。
研究设计与样本
- 开放标签研究,纳入140例抗PD-1治疗后确认进展的晚期黑色素瘤患者。
- RP1瘤内注射(≤8剂,≤10 mL/剂,允许额外给药)联合纳武利尤单抗(≤2年)。
- 主要终点为独立中心评审按RECIST v1.1评估的客观缓解率。
主要发现
- 确认ORR为32.9%(95% CI 25.2%–41.3%),完全缓解率15.0%。
- 注射与非注射病灶(包括内脏病灶)的缓解频率、深度、持续时间和动力学相似。
- 中位缓解持续时间为33.7个月(95% CI 14.1–未达到)。
- 1年和2年总生存率分别为75.3%(95% CI 66.9%–81.9%)和63.3%(95% CI 53.6%–71.5%)。
- 生物标志物分析显示缓解与广泛免疫激活相关,包括CD8+ T细胞浸润和PD-L1表达增加。
关键数值与推荐
- 治疗相关不良事件:1/2级77.1%,3级9.3%,4级3.6%,无5级事件。
- 患者特征:48.6%为IVM1b/c/d期,65.7%为原发性抗PD-1耐药,56.4%为PD-L1阴性,46.4%既往接受过抗PD-1和抗CTLA-4治疗。
临床怎么用
- 对于抗PD-1治疗失败的晚期黑色素瘤患者,RP1联合纳武利尤单抗可作为潜在治疗选择。
- 治疗期间需监测免疫相关不良事件,但总体安全性以1/2级为主。
局限性
- 单臂研究设计,缺乏随机对照,结论需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Effective treatment options for melanoma after immune checkpoint blockade failure are limited. RP1 (vusolimogene oderparepvec) is a herpes simplex virus type 1-based oncolytic immunotherapy, here evaluated in combination with nivolumab in anti-PD-1-failed melanoma. METHODS: Patients had advanced melanoma that had confirmed progression on anti-PD-1 (≥8 weeks, last prior treatment). RP1 was administered intratumorally (≤8 doses, ≤10 mL/dose; additional doses allowed) with nivolumab (≤2 years). The objective response rate (ORR) was assessed by independent central review using Response Evaluation Criteria in Solid Tumors version 1.1. RESULTS: Of 140 patients enrolled, 48.6% had stage IVM1b/c/d disease, 65.7% had primary anti-PD-1 resistance, 56.4% were PD-L1 negative, and 46.4% received prior anti-PD-1 and anti-cytotoxic T-lymphocyte antigen-4 therapy (43.6% in combination and 2.9% sequentially). Confirmed ORR (95% CI) was 32.9% (95% CI, 25.2% to 41.3%; 15.0% complete response). Responses occurred with similar frequency, depth, duration, and kinetics for injected and noninjected, including visceral lesions. The median (95% CI) duration of response was 33.7 (95% CI, 14.1 to not reached) months. Overall survival rates (95% CI) at 1 and 2 years were 75.3% (95% CI, 66.9% to 81.9%) and 63.3% (95% CI, 53.6% to 71.5%), respectively. Biomarker analysis demonstrated broad immune activation associated with response, including increased CD8+ T-cell infiltration and PD-L1 expression. Treatment-related adverse event rates were 77.1% grade 1/2, 9.3% grade 3, 3.6% grade 4, and no grade 5 events. CONCLUSION: RP1 combined with nivolumab provided deep and durable systemic responses in patients with anti-PD-1-failed melanoma, including those with poor prognostic factors. The safety profile was favorable, with mostly grade 1/2 adverse events.
引用
- Wong MK, Milhem MM, Sacco JJ, et al. RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE). J Clin Oncol. 2025. PMID: 40627813. doi:10.1200/JCO-25-01346
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。